Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Kangfang Biopharmaceutical, allowing Jichuan to exclusively commercialize the innovative drug Inusimab in China, excluding Hong Kong, Macau, and Taiwan [1] Group 1: Agreement Details - Jichuan Pharmaceutical's wholly-owned subsidiary will pay a total of 80 million yuan (including tax) as an authorization fee to Kangfang [1] - Additionally, Jichuan will pay up to 10 million yuan (including tax) in milestone payments [1] Group 2: Product Information - Inusimab is a PCSK9 monoclonal antibody developed by Kangfang, primarily used for treating primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia with atherosclerotic cardiovascular disease [1] Group 3: Strategic Implications - The transaction is expected to enhance Jichuan's product line, contributing to the sustainable development of the company's business and aligning with its long-term strategic interests [1]

伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公 司(以下合称"康方生物")与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医 药有限公司(以下合称"济川药业")于近日签署《独佔性商业化权益协议》，康方生物授权济川药业在合 作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发 并已获批上市的伊喜宁®(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获得由济川药 业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付款 ...

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...

伊喜宁®(伊努西单抗注射液)是本公司自主开发创新PCSK9单克隆抗体新药，于2024年9月获批上市，用 于治疗原发型高胆固醇血症和混合型高脂血症，包括杂合子家族性高胆固醇血症(HeFH)及同时患有动 脉粥样硬化性心血管疾病的高胆固醇血症。目前，伊喜宁®已被纳入最新版国家医保目录，并被全面管 理血脂相关心血管风险中国专家共识(2025版)和县域血脂异常合理用药与综合管理指南(2025版)重磅推 荐。 伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方 (广东)医药有限公司(以下合称"康方生物")与湖北济川药业股份有限公司全资子 ...

伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 伊喜宁®(伊努西单抗注射液)是本公司自主开发创新PCSK9单克隆抗体新药，于2024年9月获批上市，用 于治疗原发型高胆固醇血症和混合型高脂血症，包括杂合子家族性高胆固醇血症(HeFH)及同时患有动 脉粥样硬化性心血管疾病的高胆固醇血症。目前，伊喜宁®已被纳入最新版国家医保目录，并被全面管 理血脂相关心血管风险中国专家共识(2025版)和县域血脂异常合理用药与综合管理指南(2025版)重磅推 荐。 智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方 (广东)医药有限公司(以下合称"康方生物")与湖北济川药业股份有限公司全资子 ...

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 伊喜寧®通過特異性結合PCSK 9並阻斷其與LDL -R的相互作用，恢復LDL -R的表達 水平以提升對血漿中LDL -C的清除能力。既往研究表明，在他汀類藥物背景治療 的基礎上接受PCSK 9單抗治療可顯著減少人體的膽固醇水平，降低患者心臟病發 作和中風的風險。III期臨床研究顯示，伊喜寧®對於超高危、極高危、高危及中 低危分層的患者，以及無論LDL -C情況的患者，均具有優異臨床療效，為高膽固 醇血症的臨床治療、心血管風險的長期控制提供了新的選擇。 關於康融東方（廣東）醫藥有限公司 （股 份 代 號：9926） 自願公告 康方生物授予濟川藥業伊喜寧®的獨家商業化權益 康方生物科技（ 開曼 ）有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊 發，以告知 ...

Investment Projects - Huangshan Tourism plans to invest approximately 530 million yuan in the construction of the Huangshan Binjiang East Road No. 12 hotel project, with a total construction area of 79,178.15 square meters and a construction period of 24 months [2] - Xuguang Electronics intends to raise no more than 1 billion yuan through a private placement to fund projects including the expansion of high-voltage vacuum arc extinguishing chambers and other R&D initiatives [4] - Jichuan Pharmaceutical's subsidiary has paid 80 million yuan for exclusive commercialization rights of the Inusimab injection, indicating a strategic move into the biopharmaceutical market [5] Stock Performance and Risks - Hangdian Co. reported a significant stock price increase of 32.97% over three trading days, but warns of potential trading risks due to a negative rolling P/E ratio and expected net loss of approximately 300 million yuan for 2025 [3] - Sanbian Technology and Tiantong Co. both experienced abnormal stock price fluctuations, with no undisclosed significant information affecting their operations [6][7] - Wanfeng Co. noted a stock price increase of 46.43% while highlighting uncertainties regarding the price changes of core intermediate products and their impact on future earnings [8] Financial Performance - Gaotie Electric reported a net profit of 51.46 million yuan for 2025, a year-on-year increase of 14.02%, with total revenue of 1.181 billion yuan, up 17.16% [10] - Yaokang Bio achieved a net profit of 144.40 million yuan, reflecting a 31.49% increase year-on-year, driven by improved overseas sales and domestic demand recovery [11] - Babi Foods reported a slight decline in net profit to 273 million yuan, despite a revenue increase of 11.22% to 1.859 billion yuan, indicating challenges in maintaining profitability [12] - Zhongyuan Media's net profit rose by 30.99% to 1.349 billion yuan, despite a revenue decline of 5.13% [13] Shareholding Changes - Shangluo Electronics' controlling shareholder plans to reduce their stake by 3% due to personal financial needs [15] - Yilian Technology's shareholder intends to reduce their holdings by up to 2% within three months [16] - Wuxi Zhenhua's shareholders plan to reduce their stakes by 2% and 1% respectively [17] - Changchun Yidong's shareholder intends to reduce their stake by 3% through various trading methods [18] Major Contracts - Yitong Century has been pre-selected for a 1.07 billion yuan comprehensive maintenance service project with China Tower [20] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025, contributing to a total of 1.43 billion yuan for the year [21] - Hongfuhan signed a contract worth 480 million yuan with Guangdong Quanxiang for the supply of robots and related products, which is expected to significantly impact future earnings [22]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Kangfang Biopharmaceutical, granting Jichuan the exclusive rights to commercialize the approved drug Inusimab Injection in mainland China for a specified period [1] Group 1: Agreement Details - Jichuan Pharmaceutical's wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd., and Jiangsu Jiyuan Pharmaceutical Co., Ltd. have entered into an agreement with Kangfang Biopharmaceutical Co., Ltd. and Kangrong Dongfang (Guangdong) Pharmaceutical Co., Ltd. [1] - Jichuan will pay a total of 80 million yuan (including tax) as a licensing fee and up to 10 million yuan (including tax) as milestone payments [1] Group 2: Regulatory Aspects - The transaction does not constitute a related party transaction or a significant asset restructuring, and it does not require approval from the company's board of directors or shareholders [1]